FMS-Like Tyrosine Kinase 3―Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
VON BUBNOFF, Nikolas, ENGH, Richard A, ABERG, Espen, SÄNGER, Jana, PESCHEL, Christian, DUYSTER, Justus
Published in Cancer research (Chicago, Ill.) (01.04.2009)
Published in Cancer research (Chicago, Ill.) (01.04.2009)
Get full text
Journal Article
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML
Charlet, Anne, Kappenstein, Max, Keye, Philip, Kläsener, Kathrin, Endres, Cornelia, Poggio, Teresa, Gorantla, Sivahari P., Kreutmair, Stefanie, Sänger, Jana, Illert, Anna L., Miething, Cornelius, Reth, Michael, Duyster, Justus, Rummelt, Christoph, von Bubnoff, Nikolas
Published in Leukemia (01.03.2022)
Published in Leukemia (01.03.2022)
Get full text
Journal Article
Sequential Inhibitor Therapy in CML: In Vitro Simulation Elucidates the Pattern of Resistance Mutations after Second- and Third-Line Treatment
BAUER, Robert C, SÄNGER, Jana, PESCHEL, Christian, DUYSTER, Justus, VON BUBNOFF, Nikolas
Published in Clinical cancer research (01.06.2013)
Published in Clinical cancer research (01.06.2013)
Get full text
Journal Article
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors
VON BUBNOFF, Nikolas, VEACH, Darren R, MILLER, W. Todd, WANQING LI, SÄNGER, Jana, PESCHEL, Christian, BORNMANN, William G, CLARKSON, Bayard, DUYSTER, Justus
Published in Cancer research (Chicago, Ill.) (01.10.2003)
Get full text
Published in Cancer research (Chicago, Ill.) (01.10.2003)
Journal Article
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor
von Bubnoff, Nikolas, Veach, Darren R., van der Kuip, Heiko, Aulitzky, Walter E., Sänger, Jana, Seipel, Petra, Bornmann, William G., Peschel, Christian, Clarkson, Bayard, Duyster, Justus
Published in Blood (15.02.2005)
Published in Blood (15.02.2005)
Get full text
Journal Article
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)
von Bubnoff, Nikolas, Manley, Paul W., Mestan, Jurgen, Sanger, Jana, Peschel, Christian, Duyster, Justus
Published in Blood (15.08.2006)
Published in Blood (15.08.2006)
Get full text
Journal Article